Inclusion Criteria:

- Patients with microscopic stage II or IIIA resectable gastric cancer

- Patients who have not received preoperative cancer therapy (radiotherapy,
chemotherapy or immunotherapy)

- Patients with serum immunosuppressive acidic protein (IAP) measured within 2 weeks
before surgery

- Patients with no metachronous or synchronous multiple cancer

- Patients without severe impairment of renal, hepatic and bone marrow functions

- Patients who are judged to be capable of tolerating surgery

- Patients with preoperative performance status 0 to 2

- Patients with no serious concurrent complications (such as bone marrow suppression,
diarrhea and infection)

- Patients who are judged to be capable of tolerating this treatment, and who have
given written informed consent to participate in this study

Exclusion Criteria:

- Patients with fresh hemorrhage from the gastrointestinal tract

- Patients with retention of body fluid necessitating treatment

- Patients with infection, intestinal palsy or intestinal occlusion

- Patients who are pregnant or hope to become pregnant during the study period

- Patients with diabetes treated by continuous use of insulin or showing poor glycemic
control

- Patients with a history of ischemic heart disease

- Patients with concurrent psychiatric disease or psychotic symptoms, and judged to
have difficulties participating in the study

- Patients receiving continuous administration of steroids

- Patients who have experienced serious drug allergy in the past

- Others, patients judged by the investigator or subinvestigator to be inappropriate as
subject